news
Sanofi and Regeneron announce patient enrollment in two Phase 3 trials with sarilumab in RA
15 May 2013 | By Sanofi
Comprehensive SARIL-RA development program to include 2,600 patients in four Phase 3 and one open-label extension trials...
List view / Grid view
Sanofi
news
Sanofi appoints two new Members to the Executive Committee to lead the new Commercial Organization
2 May 2013 | By Sanofi
A new commercial organization to better align with its business priorities...
news
Once-daily AUBAGIO® delayed onset of clinically definite multiple sclerosis (MS) in TOPIC study
25 April 2013 | By Sanofi
Genzyme announced positive top-line results from the TOPIC trial for AUBAGIO...
news
Sanofi and DNDi celebrate six years of collaboration in fighting malaria
25 April 2013 | By Sanofi
More than 200 million treatments of ASAQ Winthrop have been distributed in Africa...
news
Sanofi reinforces its presence in Morocco
17 April 2013 | By Sanofi
Sanofi announced the opening of its new logistics hub in Casablanca, Morocco...
news
Sanofi and PATH announce the launch of large-scale production of semisynthetic artemisinin against Malaria
11 April 2013 | By Sanofi
A pivotal milestone in the fight against malaria...
news
Sanofi to invest USD 75 million in a new manufacturing facility in Vietnam
29 March 2013 | By Sanofi
“This new production and development center is the largest investment ever made by Sanofi in Vietnam..."
news
Sanofi and Transgene announce innovative long-term collaboration
25 March 2013 | By Sanofi
Creation of a new state-of-the-art industrial platform at Genzyme’s unit in Lyon...
news
Effect of Genzyme’s LEMTRADA maintained in patients beyond two-year pivotal MS studies
21 March 2013 | By Sanofi
Results from the first year of the extension study of LEMTRADA™ (alemtuzumab)...
news
Sanofi launches 2013 Patient Group Bursary Scheme
21 March 2013 | By Just:: Health PR
2013 Patient Group Bursary Scheme launched...
news
Sanofi and Regeneron report positive proof-of-concept data for Dupilumab
2 March 2013 | By Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that pooled data from two Phase 1b trials with dupilumab (REGN668/SAR231893), an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting the alpha subunit of the interleukin 4 receptor (IL-4R alpha), were presented at the 71st Annual Meeting…
news
Genzyme receives company award from European Organisation for Rare Diseases
27 February 2013 | By Genzyme
Sanofi and its subsidiary Genzyme announced today that Genzyme has received a Company Award from EURORDIS...
news
Sanofi New Drug Application for Lixisenatide accepted for review by FDA
19 February 2013 | By Sanofi
Sanofi announced that the U.S. FDA has accepted for review a New Drug Application for lixisenatide...
news
ZALTRAP® (aflibercept) approved in the EU
5 February 2013 | By Sanofi
First and only agent to statistically significantly improve survival in combination with FOLFIRI chemotherapy after an oxaliplatin regimen...
news
Once-daily Lyxumia® (lixisenatide) approved for treatment of type 2 diabetes in Europe
4 February 2013 | By Sanofi
Sanofi portfolio expands to offer first once-a-day prandial GLP-1 receptor agonist...
